May 4, 2022

ROADMAPS: An online database of response data, dosing regimens, and toxicities of approved oncology drugs as single agents to guide preclinical in vivo studies (Cancer Research)

Cancer Research: ROADMAPS: An online database of response data, dosing regimens, and toxicities of approved oncology drugs as single agents to guide preclinical in vivo studies. “The Biological Testing Branch (BTB) of the U.S. National Cancer Institute (NCI) has evaluated more than 70 FDA-approved oncology drugs to date in human xenograft models. Here, we report the first release of a publicly available, downloadable spreadsheet, ROADMAPS (Responses to Oncology Agents and Dosing in Models to Aid Preclinical Studies)… that provides data filterable by agent, dose, dosing schedule, route of administration, tumor models tested, responses, host mouse strain, maximum weight loss, drug related deaths, and vehicle formulation for preclinical experiments conducted by the BTB.”

New Resources 0
April 29, 2022

Utrecht University: Microscopic tug of war with corona

Utrecht University: Microscopic tug of war with corona. “A team of biophysicists found that SARS-CoV-2 can withstand large physical forces, and this might be one of the reasons for its success. In the scientific journal PNAS, the researchers, led by prof. Jan Lipfert, who recently joined Utrecht University, presented their method. It also allows the investigation of drugs designed to prevent the coronavirus from binding.”

COVID-19 0
April 28, 2022

How Paxlovid came to be: From the germ of an idea to a vital tool against Covid (STAT News)

STAT News: How Paxlovid came to be: From the germ of an idea to a vital tool against Covid. “Charlotte Allerton, Pfizer’s head of medicine design, was making dinner — omelets — with her teenage children when she got a call from the one of company’s top development officers. He was calling with interim results from the study of an experimental antiviral for Covid-19. She pushed the food to one side and went upstairs. ‘It’s like any piece of news that you’re expecting,’ she said. ‘You can kind of tell just from the way the person speaks.’ She went directly to work. The drug in question would become Paxlovid, a medication that might finally get the pandemic under control — if only we can get it to patients.”

COVID-19 0
May 19, 2020

News Medical: New database of 14,000 known macrolactones could support drug discovery and research

News Medical: New database of 14,000 known macrolactones could support drug discovery and research. “Researchers from North Carolina State University and Collaborations Pharmaceuticals have created a free-to-use database of 14,000 known macrolactones – large molecules used in drug development – which contains information about the molecular characteristics, chemical diversity and biological activities of this structural class.”

New Resources 0
May 5, 2020

NBC News: Countries pledge $8 billion for coronavirus vaccine, but U.S. absent

NBC News: Countries pledge $8 billion for coronavirus vaccine, but U.S. absent. “An international campaign to find a vaccine for the coronavirus raised $8 billion from governments and organizations on Monday, but the United States was notably absent from the effort. The European Commission co-led a virtual conference in response to the World Health Organization’s appeal for global collaboration in the response to the pandemic, which saw support from leaders across Europe, Japan, Saudi Arabia and Canada. China, where the virus originated, was only represented by its ambassador to the European Union.”

COVID-19 0
January 15, 2020

Science: FDA and NIH let clinical trial sponsors keep results secret and break the law

Science: FDA and NIH let clinical trial sponsors keep results secret and break the law. “Science examined more than 4700 trials whose results should have been posted on the NIH website ClinicalTrials.gov under the 2017 rule. Reporting rates by most large pharmaceutical companies and some universities have improved sharply, but performance by many other trial sponsors—including, ironically, NIH itself—was lackluster. Those sponsors, typically either the institution conducting a trial or its funder, must deposit results and other data within 1 year of completing a trial. But of 184 sponsor organizations with at least five trials due as of 25 September 2019, 30 companies, universities, or medical centers never met a single deadline.”

Research & Opinion 0
January 14, 2020

BusinessWire: Kramer Levin Launches Biologics Law Blog (PRESS RELEASE)

BusinessWire: Kramer Levin Launches Biologics Law Blog (PRESS RELEASE). “Kramer Levin Naftalis & Frankel LLP today launched the Bio Law Blog, which provides insights into intellectual property law and regulatory developments for biologic medicines. The blog is edited by Kramer Levin partners Irena Royzman, Ph.D., Jonathan S. Caplan and Hannah Lee.” I wasn’t sure what “biologic medicine” was, but MedicineNet helped me out.

Security & Legal Issues 0
November 29, 2019

Chemistry World: Open access Atlas maps out microbial natural products

Chemistry World: Open access Atlas maps out microbial natural products. “A new open access database of microbial natural products has launched online. The Natural Products Atlas (NPAtlas) is free to use and contains more than 24,000 chemical structures. The tool is based on Fair data principles, making the information within it easier to search and use in secondary analysis.” I don’t put anything in RB unless I can get a basic understanding of what the resource is about. (I have skipped including items because I just didn’t get the underlying discipline or presentation.) In this case I had no idea what microbial natural products are, but I now understand better thanks to PubMed.

New Resources 0
September 10, 2018

NoCamels: Scientists Harness AI, Deep Learning To Fast-Track Drug Discovery And Development

NoCamels: Scientists Harness AI, Deep Learning To Fast-Track Drug Discovery And Development. “The cost of developing a new pharmaceutical drug, from the research and development stage to market approval, runs at about $2.6 billion, according to a 2014 report published by the Tufts Center for the Study of Drug Development (CSDD) cited by the Scientific American. It also takes between 10 to 15 years. Israeli scientists say they have developed a revolutionary smart method to discover and develop new drugs, based on artificial intelligence and machine learning, that will dramatically shorten preparation time and reduce costs.”

Research & Opinion 0
June 18, 2018

Revitalizing the drug pipeline: AntibioticDB, an open access database to aid antibacterial research and development (Journal of Antimicrobial Chemotherapy)

Journal of Antimicrobial Chemotherapy: Revitalizing the drug pipeline: AntibioticDB, an open access database to aid antibacterial research and development. “The current state of antibiotic discovery, research and development is insufficient to respond to the need for new treatments for drug-resistant bacterial infections. The process has changed over the last decade, with most new agents that are in Phases 1–3, or recently approved, having been discovered in small- and medium-sized enterprises or academia. These agents have then been licensed or sold to large companies for further development with the goal of taking them to market. However, early drug discovery and development, including the possibility of developing previously discontinued agents, would benefit from a database of antibacterial compounds for scrutiny by the developers. This article describes the first free, open-access searchable database of antibacterial compounds, including discontinued agents, drugs under pre-clinical development and those in clinical trials: AntibioticDB.” The article is free.

New Resources 0
November 3, 2017

FDA: FDA Widens Scope of Navigator – Information Tool for Expanded Access

FDA: FDA Widens Scope of Navigator – Information Tool for Expanded Access. “FDA is committed to expanding access to safe and effective treatment options for patients with rare, debilitating, and sometimes fatal diseases. These patients face unique medical challenges. Sometimes there isn’t an FDA-approved drug to adequately address the needs of a patient with a rare disease. Therefore, the agency needs to take new steps to enable more patients with unmet needs to get access to promising treatments prior to full FDA approval. Two examples of the recent steps FDA has taken in pursuit of these goals are improvements we made to our Expanded Access Program and our Orphan Drug Program.”

Tweaks & Updates 0

The ResearchBuzz Firehose is regular RB content presented as individual posts.
For digest-type posts a couple of times a day, please visit ResearchBuzz.

Want to know how to best use the Firehose for content discovery?
Check out this handy article.

Search by Category

Get RB Firehose Via EMail

Enter your email address to subscribe to ResearchBuzz Firehose and get a firehose of new posts straight to your email.

Join 2,020 other subscribers

Recent Posts

Top Posts & Pages